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AbstrACt
Introduction Major depressive disorder is the leading 
source of disability globally and current pharmacological 
treatments are less than adequate. Animal models 
such as the Flinders Sensitive Line (FSL) rats are 
used to mimic aspects of the phenotype in the human 
disorder and to characterise candidate antidepressant 
agents. Communication between the gut microbiome 
and the brain may play an important role in psychiatric 
disorders such as depression. Interventions targeting 
the gut microbiota may serve as potential treatments for 
depression, and this drives increasing research into the 
effect of probiotics and prebiotics in neuropsychiatric 
disorders. Prebiotics, galacto-oligosaccharides and 
fructooligosaccharides that stimulate the activity of gut 
bacteria have been reported to have a positive impact, 
reducing anxiety and depressive-like phenotypes and 
stress-related physiology in mice and rats, as well as 
in humans. Bimuno, the commercially available beta-
galacto-oligosaccharide, has been shown to increase 
gut microbiota diversity.
Aim Here, we aim to investigate the effect of Bimuno on 
rat anxiety-like and depressive-like behaviour and gut 
microbiota composition in the FSL model, a genetic model 
of depression, in comparison to their control, the Flinders 
Resistant Line (FRL) rats.
Methods Sixty-four male rats aged 5–7 weeks, 32 
FSL and 32 FRL rats, will be randomised to receive 
Bimuno or control (4 g/kg) daily for 4 weeks. Animals 
will be tested by an experimenter unaware of group 
allocation on the forced swim test to assessed 
depressive-like behaviour, the elevated plus maze to 
assess anxiety-like behaviour and the open field test 
to assess locomotion. Animals will be weighed and 
food and water intake, per kilogram of bodyweight, 
will be recorded. Faeces will be collected from each 
animal prior to the start of the experiment and on 
the final day to assess the bacterial diversity and 
relative abundance of bacterial genera in the gut. All 
outcomes and statistical analysis will be carried out 
blinded to group allocation, group assignments will be 
revealed after raw data have been uploaded to Open 
Science Framework. Two-way analysis of variance will 
be carried out to investigate the effect of treatment 
(control or prebiotic) and strain (FSL or FRL) on 
depressive-like and anxiety-like behaviours.
InTroducTIon
Major depressive disorder (MDD) is the 
leading source of disability globally1 and 
treatment resistance among patients is 
roughly 50%.2 Therefore, better under-
standing mechanisms behind MDD and the 
search for potential effective and novel ther-
apeutic targets are high research and health-
care priorities. Animal models are commonly 
used to mimic aspects of the phenotype of the 
human disorder and to characterise candi-
date antidepressant agents. The Flinders 
Sensitive Line (FSL) is a well-established 
and validated genetic model of depression.3 
The FSL rats are bred to display cholinergic 
sensitivity and later found to display depres-
sive-like behaviour in the forced swim test 
(FST), compared with their control strain, 
the Flinders Resistant Line (FRL) rats.3 FSL 
rats respond to acute and chronic antide-
pressant administration and display reduced 
hippocampal plasticity4 and elevated rapid 
eye movement (REM) sleep5 in comparison 
to FRL rats.
Communication between the gut micro-
biome and the brain may play a role in 
psychiatric disorders, with research focusing 
on the bidirectional signalling at the neural, 
hormonal and immunological levels.6 Inter-
ventions targeting the gut microbiota may 
serve as potential treatments for depres-
sion, and this drives increasing research into 
the effect of probiotics and prebiotics in 
neuropsychiatric disorders. Probiotics have 
been defined as ‘live organisms, that when 
ingested in adequate amounts, exert health 
benefits.’7 Several probiotic strains have been 
investigated in psychiatric disorders and have 
reported effects on behaviour and physiology 
in laboratory animals and humans (for a 
review see Wang and colleagues8). Commer-
cially available probiotic products, ‘Ecological 
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Barrier’ and ‘Probio'Stick’, have been tested in FSL rats.9 10 
Prebiotics, defined as substrates that are selectively used 
by a host organism providing a health benefit,11 have also 
been reported to have a positive impact, reducing anxiety 
and depressive-like phenotypes and stress-related physi-
ology in mice and rats12–17 and in humans.18 19 Further, 
prebiotics have been shown to increase the diversity of 
gut microbial composition, with evidence from mice12 
and rats.13 Thompson and colleagues,15 however, showed 
no difference in gut microbiota composition in F344 rats 
receiving prebiotics. One prebiotic that is commercially 
available is Bimuno. Bimuno contains beta-galacto-oli-
gosaccharide (B-GOS) produced from lactose in cow’s 
milk.20
These previous studies show promising effects of other 
prebiotics to reduce the depressive-like and anxiety-like 
phenotypes in stress models of depression,12 14 and resil-
ience to a stressful exposure.13 15 Bimuno shows an effect 
on anxiety-like behaviour in response to a single lipo-
polysaccharide insult17 and GOS prebiotics have an effect 
on brain-derived neurotrophic factor (BDNF) levels.16 
Based on previous studies showing promising effects of 
other prebiotics to reduce depressive-like and anxiety-like 
behaviours, we will investigate the effect of Bimuno on 
rat behaviour and gut microbiota composition in the FSL 
model, a genetic model of depression, in comparison to 
their control FRL rats.
This piece was initially submitted to BMJ Open Science 
as a registered report on 4 May 2018 and simultaneously 
uploaded to Open Science Framework (OSF). Registered 
reports are a publishing initiative designed to increase 
transparency and reproducibility of research by valuing 
high methodological quality. The registered reports 
framework involves a two-stage peer review process during 
the life-cycle of an article describing research; first, at the 
study design phase, and second at the stage of final publi-
cation of the findings.21 This initiative was introduced in 
major journals around 201322 and was inspired by proto-
cols for clinical trials. Registered reports in the context 
of in vivo animal experiments are a novel application 
of this publication framework. In comparison to animal 
experiments, clinical trials typically have a longer plan-
ning stage. Protocols for clinical trials are a requirement 
when seeking regulatory approval for interventions.23 
Further, the sites of clinical trials are subject to inspec-
tions to check if the conduct of the trial is compliant with 
the protocol.24 Animal studies are often quicker to design 
and conduct with new hypotheses being generated quickly 
from previous studies, and the reporting guidelines for 
animal studies are less strictly adhered to. The protocols 
for animal studies that are conducted to support a Food 
and Drug Administration approval application require 
a sign-off from the sponsor.25
The increase of publishing registered reports sees many 
benefits, including an increase in measures to reduce 
the risk of bias and increased replicability.26 The appli-
cation of the registered reports publishing framework to 
animal experiments can improve poor reporting, which 
threatens reproducibility.27 However, the framework may 
need amending to fully reap the benefits. This report was 
initially submitted on 4 May 2018. The first peer review 
comments were received on 11 September 2018 and 
the second round of peer review comments was received 
in November, 6 months later. Within the time constraints 
of a 3-year funding window of a PhD project, the experi-
ment was conducted without completing the peer review 
process at the study design phase. The piece is therefore 
to be submitted as a ‘Protocol’.
Hypotheses
We hypothesise that FSL animals receiving Bimuno prebi-
otics will display reduced depressive-like behaviour in the 
FST and reduced anxiety-like behaviour in the elevated 
plus maze (EPM) in comparison to control (substance 
without active ingredients, Bimuno free sugars [BFS]). We 
aim to contribute to the literature describing the behav-
ioural effects of prebiotics in animal models of depres-
sion. As our secondary outcome, we hypothesise that FSL 
animals receiving prebiotics will display increased diver-
sity in the gut microbiome, in comparison to FSL animals 
receiving control, as measured on true beta diversity. 
We want to analyse gut microbiome diversity because we 
hypothesise that this is the mechanism through which 
prebiotics influence behaviour, we therefore aim to shed 
light on the commensal influence of prebiotics.28 We 
hypothesise that animals receiving Bimuno prebiotics 
will have altered weight and food intake in comparison to 
animals receiving control.
MetHods
Animals
Male FSL and FRL rats aged 5–7 weeks bred in-house at 
Translational Neuropsychiatry Unit, Aarhus University, 
will be used. Animals are bred in a closed breeding colony. 
Animals will be transferred from the closed breeding 
colony to a conventional animal facility and housed here 
for the duration of the experiment. All animals bred 
in-house are checked every 3 months for infectious agents 
in accordance with the Federation of European Labora-
tory Animal Science Associations (FELASA) recommen-
dations.29 Animals did not have any known infections at 
the start of the experiment and were healthy, as assessed 
by FELASA-accredited in-house animal technicians.
Animals will be housed in pairs in standard cages with 
a plastic bottom and metal rack top half, purchased from 
Tecniplast, Italy (Cage 1291H Eurostandard Type III H, 
425×266×185 mm). The bedding material in each cage will 
be made out of wooden chips (aspen wood from Tapvei, 
Finland) along with access to a tunnel shelter, nesting 
material and a wooden stick. Animals will be maintained 
in a 12-hour light/dark cycle with lights off at 13:00 hours. 
Seven days prior to the start of the experiment, the 
animals will be moved to the animal housing facility and 
the new lightning regime will start immediately. Animals 
will be under the care of FELASA-accredited in-house 
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animal technicians. Animals will have tap water and stan-
dard chow (purchased from Brogaarden, Altomen 1324).
Power calculation to determine the number of animals
Our sample size calculations are based on published 
behavioural findings from Burokas and colleagues12 and 
McVey Neufeld and colleagues.14
Data were extracted from Burokas et al,12 who inves-
tigated the effects of prebiotics in the FST using male 
C57L/6J mice (figure 6D in the publication). These 
data (mean, SEM and group numbers) were used to run 
a one-way analysis of variance (ANOVA) and determine 
an eta squared (=SSbetween/SStotal) of 0.579. This 
eta squared value was used to compute the effect size, 
f=
 
(
√(
eta2
1−eta2
)
)
 
, which is 1.1747. This effect size was used 
in the power calculation carried out in R (V.3.4.3) using 
the function ‘ pwr. anova. test’. A significance level of 0.01 
and a power of 0.9 were chosen. This gave the result of 
six experimental units per group. An experimental unit 
is the entity subjected to an intervention independently 
of all other units where it is possible to assign two experi-
mental units to different treatment groups.30
Data were extracted from McVey Neufeld et al,14 who 
used prebiotics and probiotics in a maternal separation 
model of depression in the open field using male Sprague-
Dawley rats. Data are from the amount of time spent in 
the centre of the open field (figure 1B in the publication) 
for the model group. These data (mean, SD or SEM, and 
group numbers) were used to run a one-way ANOVA and 
determine an eta squared (=SSbetween/SStotal) of 0.522. 
This eta squared value was used to compute effect size, 
f=
 
(
√(
eta2
1−eta2
)
)
 
, which is 1.046. This effect size was used 
in the power calculation carried out in R (V.3.4.3) using 
the function ‘ pwr. anova. test’. A significance level of 0.01 
and a power of 0.9 were chosen. This gave the result of six 
experimental units per group.
Based on the a priori sample size calculations above 
and experience from previous in-house experiments, a 
conservative estimate of sample size for this study of eight 
experimental units per group was selected. This number 
is two per group larger than the power calculation and 
was selected to account for possible attrition or possible 
exclusions throughout the experiment (see criteria 
below). With eight experimental units per group, power 
of 90% and a significance level of 0.01, we are powered 
to detect an effect of f=0.86. This effect size we consider 
biologically relevant, in order to see a relevant reduc-
tion in immobility behaviour in the FST. The full R code 
for these calculations is provided on the Open Science 
Framework project: .
Prebiotics administration
The prebiotic and control treatment will be administered 
for 28 consecutive days (4 weeks). The treatments will be 
administered within the first hour after lights off, the first 
hour of the animals’ active phase.
We will use the commercially available prebiotic product 
‘Bimuno’ Powder (Bimuno, UK), which contains B-GOS. 
A dose of 4 g/kg dissolved in tap water will be used per 
animal per day, administered by syringe feeding. The 
dose will be adjusted each week according to the weight 
of the animals. This prebiotic was chosen due to its supe-
rior effect over fructooligosaccharides.16 This dose was 
given to recreate the findings in previous literature.16 31
Control administration
The control for the prebiotics will be the BFS (consisting 
of 50% lactose, 27% glucose and 23% galactose). The 
control will be administered at a dose of 4 g/kg/day. This 
follows the dosing regimen of previous literature.16 31 This 
control will be administered simultaneously to the preb-
iotics administration via syringe feeding in a volume of 
2 mL. The dose will be adjusted each week according to 
the weight of the animals.
syringe feeding details
Treatment will be administered via syringe feeding; the 
prebiotic, within a sweetened vehicle of glucose, is mixed 
with tap water, and added to a syringe. This is a newly 
established method for the accurate individual dosing 
of probiotics in rats.32 With a training phase of roughly 
3–4 days, to allow the rats to become accustomed to the 
administration and the taste, the rats willingly consume 
the mixture and approach the edge of the cage when the 
syringe is presented. This new method has been used for 
volumes of probiotic+vehicle solution up to 3 mL. This 
method of administration has been chosen to reduce 
the stress associated with oral gavage, and to increase the 
accuracy of dosing with administration of prebiotics in 
drinking water. In this experiment, the prebiotic Bimuno 
will be added to tap water to give a total volume of 2 mL, 
as the smaller the volume, the sweeter the solution, which 
is thought to be more desirable for the rats to consume. 
Animals will be fed at the start of the active cycle, within 
the first hour after lights off.
Measures to reduce the risk of bias
Randomisation to treatment and control and allocation 
concealment
On the first day of the experiment, animals will be moved 
from the breeding facility into the experimental facility. 
Animals are pair housed; the two animals in each cage 
will be the same strain and will receive the same treat-
ment. Cages will be randomly assigned to a group, 
treatment or control, to ensure allocation concealment 
during the handling and administration of treatment 
throughout the experiment. Randomisation will be 
carried out using block randomisation with the online 
tool, the Sealed Envelope (https://www. sealedenvelope. 
com/ simple- randomiser/ v1/ lists), by a colleague not 
involved in the day-to-day running of the experiment. 
Cages will be labelled with a unique randomisation code 
(eg, GU9, LI3, and so on) and a list of which treatments 
are given to which cage will be read off each day. This is 
 o
n
 27 M
ay 2019 by guest. Protected by copyright.
http://openscience.bmj.com/
BM
J O
pen Science: first published as 10.1136/bmjos-2018-000017 on 1 May 2019. Downloaded from 
4 Bannach-Brown A, et al. BMJ Open Science 2019;3:e000017. doi:10.1136/bmjos-2018-000017
Open access 
to minimise potential unconscious bias by ‘remembering’ 
which cages get which treatment. Treatments will be 
identified as A or B. The cages (the experimental unit) 
will be assigned randomly to treatment and the observa-
tional unit is the individual animal where the outcome of 
interest is measured. The observational unit (the animal) 
is nested within the experimental unit. The order of the 
cages will be randomised in the racks at the beginning 
of the experiment so as to reduce possible effects from 
air-conditioning vents and/or being closer to the door. 
The placement of the cage will not be taken into consid-
eration as a variable during analysis of the outcome data. 
Animals will have 7 days to acclimatise to new housing 
facilities. When the experiment and treatment adminis-
tration begins, the experimenter will be blinded to which 
solution (prebiotic or vehicle control) each rat receives. 
The prebiotics and free sugars are delivered in unmarked 
sachets (only with company logo and batch number) of 
3.56 g. Sachets will be removed from their identifying 
boxes and moved into plastic boxes marked, for example, 
A+B, to signify which groups will receive the sachets, by a 
colleague not involved in the day-to-day running of the 
experiment. They will put enough sachets for the dura-
tion of the experiment. This allows the primary experi-
menter to prepare and administer the treatments each 
day for 28 days in a blinded manner.
Blinded assessment of primary outcome
The primary outcome is the FST. This outcome is 
recorded on video and scored manually. The videos will 
be assessed blinded, before the group identity of the 
animals is revealed. The same procedure will be carried 
out for the open field test. All videos will be analysed 
after all behavioural outcomes have been carried out. 
The primary experimenter will be formally unblinded to 
the true group identity after data analysis files have been 
uploaded to OSF.
outcome assessment
Behavioural assessment will occur during the rats’ active 
phase, starting approximately 1 hour after administration 
of prebiotics, 1 hour after lights off, and lasting approxi-
mately 3 hours, until 4 hours after lights off.
Forced swim test
On day 26 of the experiment, 1 hour after lights off, at 
the start of the animals’ active phase, the FST will be 
performed. Clear glass cylinders (60 cm h×24 cm Ø) 
filled with water up to 40 cm will be used. The temper-
ature of the water will be kept at 25°C±1°C. On the first 
day, the preswim session, the animals will be placed in the 
tanks for 15 min. On the second day of testing, animals 
will be placed into the tanks for 5 min. Both sessions 
will be recorded by video camera. Both testing sessions 
will be conducted in red light conditions. Three behav-
ioural parameters will be assessed from the video footage: 
passive behaviour, immobility, and two active behaviours, 
swimming and climbing behaviours. Passive behaviour 
is defined as ‘the rat making no further movements 
beyond those needed to keep its head above the water.’9 
For each 5 s period, the predominant behaviour will be 
recorded (immobility, swimming or climbing). Counts of 
behaviour on the three behaviours will be summed and 
time spent across the swim session (5 min) will be calcu-
lated, for example, 12×5 s periods of immobility=60 s out 
of 5 min, 27×5 s periods of swimming=135 s out of 5 min, 
21×5 s periods of climbing=105 s out of 5 min. All swim-
ming sessions will be scored by an experimenter blinded 
to the group assignment of the animals.
Open field test
Locomotor activity will be assessed on day 27, immedi-
ately prior to the second FST session. Locomotor activity 
will be assessed in a 100 cm×100 cm (×20 cm h) black 
open field arena. Each animal will be placed in the arena 
in the same starting location. The animals will be assessed 
for 15 min in red light because they will be tested in their 
active phase at 1 hour after lights off. All sessions will be 
video recorded and analysed using Noldus EthoVision 
XT9. Locomotor activity will be measured from the video 
recording, assessed as the distance each animal moved 
in centimetres. The arena will be cleaned with ethanol 
between each animal. All video recordings will be scored 
by an experimenter blinded to the group assignment of 
the animals.
Elevated plus maze
Anxiety behaviour will be assessed on day 24 in the EPM. 
The plus-shaped maze has two open arms and two closed 
arms (length: 50 cm×width: 10 cm) and the centre zone 
measures 10 cm×10 cm. Each animal will be placed in the 
arena in the centre, facing the same open arm. Animals 
will be assessed for 5 min and will be tested during their 
active phase, 1 hour after lights off. The light intensity in 
the open arms will be 80–100 lx and 20 lx in the closed 
arms. Animals will be kept in an adjacent dark exper-
imental room and moved individually into the bright 
experimental room for testing. All sessions will be video 
recorded and analysed using Noldus EthoVision XT9. 
Anxiety behaviour will be measured by calculating the 
time spent in the open arms in proportion to the time 
spent in the open arms and closed arms and number of 
entries into open arms (defined as the entire body of 
the rat in the open arm). The arena will be cleaned with 
ethanol between each animal. All video recordings will be 
scored by an experimenter blinded to the group assign-
ment of the animals.
Body weight and food consumption
Animals will be weighed every week throughout the 
experiment to assess if prebiotics administration influ-
ences weight gain, and also to adjust the dose of the preb-
iotics or control administered (4 g/kg). Weekly food and 
water intake (per kg body weight) in the home cage will 
also be recorded.
 o
n
 27 M
ay 2019 by guest. Protected by copyright.
http://openscience.bmj.com/
BM
J O
pen Science: first published as 10.1136/bmjos-2018-000017 on 1 May 2019. Downloaded from 
 5Bannach-Brown A, et al. BMJ Open Science 2019;3:e000017. doi:10.1136/bmjos-2018-000017
Open access
Microbiota analysis
Faecal boli will be collected at the start of the experiment 
(day 1) and on day of euthanisation (day 28). Faecal boli 
at the start and end of the experiment will be collected 
directly from each animal into sterile tubes and frozen 
and stored at −80°C. Faecal boli will be used to analyse the 
composition of gut microbiota. DNA will be isolated from 
the faecal boli using the isopropanol DNA extraction 
method.33 16S rRNA amplicon sequencing on V4-5 will be 
carried out on faecal boli from individual animals. Broad 
sequencing will be carried out by an external biotech 
company, DNA Sense, in Aalborg, Denmark. The alpha 
diversity, the beta diversity and the abundance of genera, 
more specifically, the relative abundance of Bifidobac-
terium and Lactobacillus genera, will be analysed as GOS 
prebiotics have previously been shown to enhance diver-
sity and these specific genera.12 34 35
Dissection
Animals will be euthanised on day 28 and the whole brain 
will be removed. Brains will be stored in formaldehyde 
at −20°C. Brain chemistry analyses to assess neurotrans-
mitter receptor mRNA expression and growth factors, 
such as BDNF, will be carried out, funding permitting. 
A protocol annex for these additional analyses will be 
submitted to the OSF prior to commencement.
exclusion criteria
1. Animals will be excluded from the study if they, at any 
point during the study, display illness as assessed by 
trained, in-house veterinarians on a daily basis. Animals 
will be euthanised immediately to end suffering.
2. No animals will be excluded from the statistical analy-
sis if they successfully complete all aspects of the study. 
Data for each animal will be included in analysis of the 
individual tests if they completed the test. If an animal 
does not complete the open field test they will be re-
moved from the FST analysis as we would be unable to 
exclude the impact of hyperlocomotion of activity in 
the FST.
3. Potential reasons why an animal might not complete 
an aspect of the study include technical difficulties 
during the video recording, or other circumstances 
where the raw data or data collection process has been 
compromised and statistical analysis is not possible.
4. There are no exclusion criteria based on performance 
on behavioural tests.
5. Potential reasons why an animal might be excluded 
from microbial analysis include failure to produce fae-
cal boli on two separate occasions during the day of col-
lection, or technical difficulties during the sequencing.
Experimental procedure
Step 1: Animals are bred in-house. At 5–7 weeks of age, 
rats will be moved into experimental housing and have 
a 7-day acclimatisation/habitation period to the animal 
housing facility prior to the start of the experiment. The 
FSL and FRL rats will be randomised into two groups: 
treatment and control. 
Step 2: On day 1 of the experiment, each rat will be 
weighed and faecal boli will be collected. Then the first 
administration of prebiotics or control will be given.
Step 3: Animals will remain continuously on this treat-
ment regimen for 4 weeks (28 days). Rats will be weighed 
every week. The animals’ daily food and water consump-
tion will be recorded.
Step 4: On day 24, animals will be subjected to the EPM.
Step 5: On day 26, animals will be subjected to the preswim 
of the FST.
Step 6: On day 27, the open field test and the FST will be 
carried out.
Step 7: On day 28, animals will be euthanised and brains 
will be harvested from all animals.
The timing of outcome assessments is displayed in 
table 1and Figure 1. 
data analysis pipeline
Data from the open field and FST will be recorded in 
EthoVision. Videos will be stored on a network drive. 
Video from each animal will be scored blinded to the 
animal’s group assignment. Potential data transformation 
and all statistical analysis will be carried out in R Studio 
using the latest version of R.
statistical analysis
First, the data from individual animals will be averaged 
per cage to obtain a value for the experimental unit. A 
Student’s t-test will be performed to compare the perfor-
mance in the FST between the FSL and FRL rats, to 
confirm that the FSL rats do indeed display increased 
depressive-like behaviour. To test the hypothesis that 
probiotics improve depressive-like behaviour on the 
FST and anxiety-like behaviour in the EPM, the primary 
outcome being immobility time, a two-way ANOVA will 
Table 1 Timing of outcome measure administration to each group
Model Treatment
Length of administration 
(weeks) Elevated plus maze FST and open field Euthanasia
FSL Prebiotics 4 Day 24 Day 27 Day 28
FSL Control 4 Day 24 Day 27 Day 28
FRL Prebiotics 4 Day 24 Day 27 Day 28
FRL Control 4 Day 24 Day 27 Day 28
FRL, Flinders Resistant Line; FSL, Flinders Sensitive Line; FST, forced swim test. 
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be conducted with two independent variables: treatment 
(control or prebiotic) and strain (FSL or FRL). Group 
differences will be investigated with a Tukey post hoc 
test. If data are not normally distributed, a base-10 log 
transformation will be carried out. If data do not meet 
assumptions for homogeneity of variances in the ANOVA 
or t-test, a Welch correction will be used. For the ANOVA, 
a Kruskal-Wallis test will be conducted if residuals are not 
normally distributed. A Tukey post hoc test will be carried 
out to investigate group differences; this will be carried 
out also if data are corrected/transformed data. All raw 
data, transformed (if applicable), and data analysis code 
will be uploaded to Open Science Framework.
Principal coordinate analysis will be conducted based 
on 16s rRNA sequencing data to quantify the beta diver-
sity, clustering based on operational taxonomic unit, and 
to measure the relative abundance of genera. The relative 
abundance of Bifidobacterium and Lactobacillus genera, as 
well as total bacteria, will be compared between groups.
dIsCussIon, lIMItAtIons And externAl vAlIdIty 
ConsIderAtIons
The sample size calculation used to estimate the number 
of animals to be used is based on one study in mice using 
the FST12 and one study in rats using the open field test.14 
There are limitations to the use of the outcomes from 
these papers. First, we do not have published data from 
the effects of prebiotics in rats for our primary outcome, 
the FST. Therefore, we combined the use of published 
FST data from mice and published data from rats in the 
open field, our secondary outcome. This may yield an 
inaccurate appropriate sample size calculation; however, 
we are using the available published data to provide a best 
estimate.
We did not control for littermate effects in this study. 
Littermate effects could impact the similarity of micro-
biota between and within cages. If animals in a cage were 
from the same litter, they have more similar microbiota 
compared with animals in a cage from separate litters.36 If 
animals in a treatment group are from two to three litters 
compared with animals from more than three or four 
litters, this is hypothesised to be of higher variability. 
We have aimed to stabilise the effects and reduce cage 
variability somewhat by cohousing the animals for 7 days 
prior to the start of the experiment. However, the effect 
of littermate effects on microbiota variability is unknown 
in this experiment.
We aimed to measure the starting microbiome of each 
animal and measure the impact of prebiotics on the gut 
microbiome by taking faecal samples at the beginning 
and end of the experiment. Rather than controlling for 
similar gut microbiota between the animals at the start 
of the experiment, which would reduce the variability 
observed, also does not reflect a naturalistic environment.
The choice of model in this experiment will be the 
FSL rats. This model of depression has a moderate level 
of face validity3 sharing some similarities with the human 
disorder, such as elevated REM sleep and increased 
passive behaviour following stress.3 However, this model 
does not reflect the full heterogeneity of symptoms 
observed in depression in humans, and may not reflect 
the complex interplay between genetics and environ-
ment that contribute to the development of depression 
in humans. Therefore, there may be limited translat-
ability of the findings from this study directly to human 
populations.
This experiment will be conducted in male animals 
only. To ensure findings are externally valid in both 
sexes, a follow-up experiment will need to be conducted 
including both sexes to analyse the sex difference in the 
effects of prebiotics.
The choices of behavioural outcome measures that 
will be used in the experiment are EPM, open field test 
and the FST. The limitations of these behavioural tests 
have been extensively discussed elsewhere37 (Spruijt et 
al, 201438), we acknowledge the issues with lack of repro-
ducibility across studies. The order of administration of 
the tests was chosen to be conducted from least to most 
stress inducing. All animals will be tested on behavioural 
assessments in the same order: EPM, 48 hours’ rest, 
preswim of the FST, 24 hours’ rest, open field test of loco-
motion and FST test session directly after.
The prebiotics will be mixed with tap water. This 
method of administration is similar to how the prebi-
otics would be administered in human studies. Although 
there has not been an investigation into the effects of tap 
water versus autoclaved water, we thought this method 
of administration would maintain ecological validity and 
mimic the method of administration in human consump-
tion of the prebiotics.
Due to time and resource constraints, this report was not 
submitted as a registered report and instead submitted as 
a protocol. Similar projects conducting animal behaviour 
experiments in the laboratory will likely be subject to 
similar time pressures and therefore a peer review process 
of longer than 6 months is not feasible for effective imple-
mentation of registered reports in animal experiments. 
As the registered reports publishing framework is being 
Figure 1 Experimental design set-up. FRL, Flinders 
Resistant Line; FSL, Flinders Sensitive Line.
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trialled for animal experiments, we can consider the 
merits and limitations of this approach. How can the 
benefits of registered reports be reaped while fitting 
into the current academic and scientific model used in 
animal experiments? The aim is to ensure the benefits of 
openness and transparency to improve quality of both the 
reporting and the conduct of animal experiments, and 
to ensure the results from experiments are as accurate as 
possible where hypotheses are supported with adequately 
powered studies to reduce the risk of false positive and 
false negative findings.
Perhaps the current peer review process is not suit-
able for implementing registered reports for animal 
experiments. The current model in animal experimental 
work involves the conduct of many small experiments. 
Hypotheses change rapidly, and many exploratory and 
confirmatory experiments are conducted. For registered 
reports to be useful in the context of animal experi-
ments, peer review needs to be incredibly rapid in order 
to allow for the fast life-cycle of this research. An alter-
native review process may be required to expedite peer 
review comments. One potential is an online forum or 
portal where authors and reviewers can post publica-
tions and comments, and discuss. Another alternative 
may be simply to promote the more widespread use of 
protocol registration on a protocol platform. Platforms 
such as OSF can host the protocols and associated mate-
rials. Preregistration of animal experiments has been 
trialled by  preclinicaltrials. eu. Protocol registration plat-
forms can reap most of the benefits of registered reports; 
stating whether an experiment is exploratory or confir-
matory, having a clear predefined hypothesis where 
confirmatory and stating the intended methodology and 
statistical analysis plan all contribute to transparent work 
and reduce research waste in unnecessary replication of 
experiments. Reporting a priori sample size calculation 
can also contribute to improving the quality of confirma-
tory experiments performed.
Another alternative may be to rethink and restruc-
ture short research projects. Current metrics of success 
in academia are based on the number of successful or 
‘significant’ findings from experiments, and novelty of 
hypotheses or methodology is highly rewarded. A restruc-
ture would value and incentivise projects that ensure 
high-quality experiments are conducted, findings are 
replicated and have external validity. It may be neces-
sary to develop new metrics for measuring contribution 
to projects. One example of implementing this idea in 
practice comes from Button and Munafo in psychology,39 
setting up a consortium across universities for student 
projects. Best practices and protocols for projects are 
established collectively and data on the same research 
question are collected at multiple sites. An alternative 
incentive system is implemented by using the inclusive 
authorship conventions commonly used in genetics and 
physics. In principle, it is easy to set up such a consor-
tium that collaborates on testing hypotheses in animal 
experiments. Testing hypotheses across animal labs 
would ensure that findings are robust to variability in 
lab settings. By shifting the framework to a collaborative 
approach and rewarding contribution to the collabora-
tion, such as is used in these consortia, the benefits of 
conducting high-quality research can be reaped. Several 
possible changes can be made to the current paradigm to 
ensure the benefits of registered reports can be reaped 
for animal experiments. These are not mutually exclusive 
and may be implemented together for added benefit.
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